RECBIO-B - VOLUNTARY ANNOUNCEMENT

LATEST BUSINESS DEVELOPMENTS RELATING TO THE SHINGLES VACCINE AND HPV 9-VALENT VACCINE

Jiangsu Recbio Technology Co., Ltd.

江蘇瑞科生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02179)

VOLUNTARY ANNOUNCEMENT

LATEST BUSINESS DEVELOPMENTS RELATING TO THE SHINGLES

VACCINE AND HPV 9-VALENT VACCINE

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the "Board") wishes to announce the following business developments:

I. R&D PROGRESS OF THE RECOMBINANT SHINGLES VACCINE (CHO CELLS)

The new drug application for the Company's novel adjuvanted recombinant shingles vaccine REC610 ("REC610"), which is currently under development, was officially accepted by the Center for Drug Evaluation of the National Medical Products Administration on December 29, 2025, with the acceptance number being CXSS2500145. As of the date of this announcement, this vaccine candidate has successfully completed the drug clinical trial site inspection and the manufacturing site inspection for drug registration. The Company will continue to cooperate with the regulatory authorities in advancing the review process.

II. R&D PROGRESS OF THE RECOMBINANT HUMAN PAPILLOMAVIRUS TYPES 6/11/16/18/31/33/45/52/58 9-VALENT VACCINE (HANSENULA POLYMORPHA)

With respect to the original timeline disclosed in the Company's announcement dated November 11, 2024 relating to the issuance of domestic shares and its 2025 interim report, pursuant to which the marketing application for the HPV product was scheduled to be submitted by June 30, 2026, as of the date of this announcement, the Company had not completed the submission of the marketing application by such deadline. In view of the actual progress of the clinical follow-up for the product and the implementation of manufacturing process validation, the registration submission materials still require more time for further refinement. The Company will re-plan and adjust the timetable for the submission of the marketing application. To expedite the R&D and registration progress of the HPV pipeline, the Company has completed adjustments to the core management team of its HPV manufacturing segment, strengthened the overall coordination and management of

the entire process covering clinical execution, registration submission and process validation, and ensured the efficient advancement of each stage. At present, the overall progress of the HPV R&D pipeline remains within the Company's control. Should there be any material developments in the future, including the submission of a marketing application, the Company will strictly comply with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and fulfill its information disclosure obligations in a

timely manner.

RISK WARNING

Due to the high-tech, high-risk and high value-added characteristics of pharmaceutical products, significant risks and uncertainties exist in the research, development and commercialization process of pharmaceutical products. The acceptance of the new drug application for REC610 and its passing of the relevant on-site inspections do not guarantee that REC610 will ultimately obtain approval for marketing, and the Group may not successfully develop or market REC610. The timing of the submission of the marketing application for the HPV vaccine pipeline is also subject to various factors and remains uncertain.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Jiangsu Recbio Technology Co., Ltd. Mr. XU Haoyu

Chairman

Jiangsu Province, the PRC, July 23, 2026